tbuckley/cabot-search huggingface dataset:
Abstract 16991: Endothelial Nitric Oxide Synthase is Essential for Hypoxia-Induced Progenitor Cell Mobilization and Homing
Authors: Bert R Everaert, Steven J Van Laere, Vicky Y Hoymans, Jean-Pierre Timmermans, Christiaan J Vrints
Journal: Circulation (2011)

Introduction: Acute myocardial infarction (AMI) is accompanied by induction of pro-angiogenic responses that lead to the recruitment of progenitor cells (PCs). Failure to induce PC mobilization, inefficient homing towards or limited survival in the ischemic microenvironment are all associated with loss in healing capacity and increased scar formation. Hypothesis: Both endothelial nitric oxide synthase (eNOS) and hypoxia-inducible factor-1 (HIF-1) have been implicated in PC biology, angiogenesis and vascular homeostasis. We investigated the effects of eNOS deficiency on HIF-1 and HIF-1 related gene expression, PC mobilization and peripheral PC homing conditions. Methods &amp; Results: AMI was induced in wild-type (WT) (n=10) and eNOS knockout (KO) mice (n=10). One week post-AMI, bone marrow mobilization of early PCs (Lin - Sca-1 + ) was markedly attenuated under eNOS-deficient conditions (p&lt;0.001), as assessed by flow cytometry. mRNA expression of Hif1a (p&lt;0.001) and HIF-1-dependent chemotactic factors, such as Cxcl12 (p&lt;0.001) and Ccl2 (p&lt;0.05), and vascular adhesion molecules, such as Icam1 (p=0.002) and Vcam1 (p&lt;0.001), displayed significantly lower expression in the infarction border zone in eNOS KO mice. eNOS activity was highly correlated with Hif1a expression in WT animals (r=0.876, p&lt;0.0001), a relation that was completely lost in the absence of eNOS. Lin - Sca-1 + PC mobilization was correlated with Hif1a (p=0.01), Cxcl12 (p=0.018) and Ccl2 (p=0.008). Histologically, eNOS KO showed decreased capillary formation in the infarction border zone, which correlated with Hif1a (p=0.007) and Cxcl12 (p&lt;0.001) expression, vascular adhesion molecules Icam1 (p=0.003) and Vcam1 (p=0.018), and with mobilization of Lin - Sca-1 + PCs (p=0.033). Conclusions: eNOS is essential for the mobilization of PCs out of the bone marrow and the expression of hypoxia-induced chemokines and vascular adhesion molecules. We provide evidence for the close relationship between eNOS and HIF-1 pathways and suggest a novel view on PC biology in which nitric oxide acts as an essential cofactor for normal HIF-1 activity, enhancing both PC mobilization and peripheral PC homing conditions.
Phase I study of E7389 administered by 1 hour infusion every 21 days
Authors: E. H. Rubin, L. Rosen, V. Rajeev, L. Wiggins, J. Sicam, S. Silberman, G. Shapiro
Journal: Journal of Clinical Oncology (2005)

2054 Background: E7389 is a synthetic analog of halichondrin B, which was isolated from a marine sponge and has a unique profile of tubulin interactions. E7389 has a broad anti- proliferative activity at nanomolar levels. Methods: The goals of this trial were to determine the dose-limiting toxicities (DLT), the maximum-tolerated dose (MTD) and the pharmacokinetics (PK) of E7389 administered every 21 days in patients (pts) with refractory non-hematologic malignancies. Eligibility criteria included normal organ function and at most 2 previous chemotherapy regimens. Dose escalation involved an accelerated two-step design. Results: To date, 18 pts have been treated (0.25 to 4 mg/m2). Median age at enrollment was 62 years (29–73) and all had a performance status of 0 or 1. The most common tumor types were non-small cell lung cancer (6) and renal cell carcinoma (3). Three of 3 pts at 4 mg/m2 and 2/3 at 2.8 mg/m2 developed febrile neutropenia (FN), contributing to DLT at these doses. Only 1/3 pts enrolled at 2.0 mg/m2 experienced FN or any other DLT, and enrollment continues at this dose level. Other drug-related toxicities have been minor, and no pt has experienced neurotoxicity. The median number of cycles is 3.5 (1–11). No complete or partial response (by RECIST) has been observed. One pt with uterine sarcoma (previously treated with gemcitabine, paclitaxel, and carboplatin) had a 20% reduction in pelvic adenopathy, and 4 pts have had stable disease for 4 cycles or more. Analysis of plasma and urine E7389 concentrations indicates a prolonged elimination phase (average plasma half-life 34 to 73 hours) with a small fraction of drug (4–12%) excreted unchanged in the urine. Among the current dose levels, plasma Cmax and AUC appear to increase linearly with dose. Conclusions: Neutropenia is the dose-limiting toxicity for E7389, with an expected MTD of 2 mg/m2 administered every 21 days. An update on safety and efficacy will be provided. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eisai Eisai
Comparative Studies on Host Responses to Shope Fibroma Virus in Adult and Newborn Rabbits2
Authors: Jerry W. Smith, Satvir S. Tevethia, Barnet M. Levy, William E. Rawls
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Comparative Studies on Host Responses to Shope Fibroma Virus in Adult and Newborn Rabbits Get access Jerry W. Smith, Jerry W. Smith Department of Virology and Epidemiology, Baylor College of Medicine; and University of Texas Dental Branch, Houston, Texas 77025 Search for other works by this author on: Oxford Academic PubMed Google Scholar Satvir S. Tevethia, Satvir S. Tevethia Department of Virology and Epidemiology, Baylor College of Medicine; and University of Texas Dental Branch, Houston, Texas 77025 Search for other works by this author on: Oxford Academic PubMed Google Scholar Barnet M. Levy, Barnet M. Levy Department of Virology and Epidemiology, Baylor College of Medicine; and University of Texas Dental Branch, Houston, Texas 77025 Search for other works by this author on: Oxford Academic PubMed Google Scholar William E. Rawls William E. Rawls 5 Department of Virology and Epidemiology, Baylor College of Medicine; and University of Texas Dental Branch, Houston, Texas 77025 5Send reprint requests to: Dr. William E. Rawls, Department of Virology and Epidemiology, Baylor College of Medicine, Houston, Texas 77025. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 50, Issue 6, June 1973, Pages 1529–1539, https://doi.org/10.1093/jnci/50.6.1529 Published: 01 June 1973 Article history Received: 13 October 1972 Accepted: 07 February 1973 Published: 01 June 1973
Cyclic Nucleotide Concentrations in 7,12-Dimethylbenz[a]anthracene-Induced Pancreatic Cancer in Rats2
Authors: R. H. Stevens, J. M. Graves, E. S. Meek, J. W. Osborne, H. F. Cheng, D. P. Loven
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article Cyclic Nucleotide Concentrations in 7,12-Dimethylbenz[a]anthracene-Induced Pancreatic Cancer in Rats Get access R. H. Stevens, R. H. Stevens 3Radiation Research Laboratory, Department of Radiology, University of Iowa, Iowa City, Iowa 52242. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. M. Graves, J. M. Graves 3Radiation Research Laboratory, Department of Radiology, University of Iowa, Iowa City, Iowa 52242. Search for other works by this author on: Oxford Academic PubMed Google Scholar E. S. Meek, E. S. Meek 4Department of Pathology, University of Iowa. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. W. Osborne, J. W. Osborne 3Radiation Research Laboratory, Department of Radiology, University of Iowa, Iowa City, Iowa 52242. Search for other works by this author on: Oxford Academic PubMed Google Scholar H. F. Cheng, H. F. Cheng 3Radiation Research Laboratory, Department of Radiology, University of Iowa, Iowa City, Iowa 52242. Search for other works by this author on: Oxford Academic PubMed Google Scholar D. P. Loven D. P. Loven 3Radiation Research Laboratory, Department of Radiology, University of Iowa, Iowa City, Iowa 52242. 5We are indebted to J. Peiffer and J. Poulsen for their excellent secretarial assistance in the preparation of this manuscript; we especially thank A. J. Lawson, D. W. White, and D. L. Pingel for their technical contributions. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 61, Issue 5, November 1978, Pages 1281–1283, https://doi.org/10.1093/jnci/61.5.1281 Published: 01 November 1978 Article history Received: 09 February 1978 Accepted: 30 May 1978 Published: 01 November 1978
Clinical utility of FDG-PET for evaluation of the viability in post-chemotherapeutic residual lesions in pediatric solid tumors
Authors: A. Hosono, A. Makimoto, N. Tsuji, H. Kawamoto, A. Watanabe, U. Tateishi, T. Terauchi
Journal: Journal of Clinical Oncology (2006)

9067 Background: Exact evaluation of viability in post-chemotherapeutic residual lesions in patients with solid tumors should allow us to select the appropriate therapeutic options. F-18 fluorodeoxyglucose position emission tomography (FDG-PET) is one of the promising modality to evaluate it without invasive procedure. Methods: The cohort is a total of 14 patients with pediatric solid tumors (rhabdomyosarcoma 7, Ewing sarcoma 4, Wilms tumor 2 and neuroblastoma 1), which are either newly diagnosed or newly relapsed between January 2005 and December 2005. A total of 15 residual tumors from the 14 patients after chemotherapy underwent 51 FDG-PET scans. Seven residual tumors out of 6 patients, who were newly diagnosed, and another 8 tumors out of 8 patients, who were relapsed, were evaluated after induction or reinduction chemotherapy. Parameters of FDG-PET were assessed by area of FDG uptake and standardized uptake values (SUV). Results of FDG-PET were compared either with histological examination of the residual tumors (n=11) or with the clinical status 6-month after the last FDG-PET (n=4) in order to judge whether the findings of FDG-PET were true or false. Results: Three of 15 residual lesions showed increased SUV, while 12 lesions obtained negative SUV. Three lesions with positive SUV consisted of 2 true-positive and 1 false-positive lesions. Among twelve lesions were negative SUV, 11 lesions were true-negative, and 1 was false-negative. The sensitivity and specificity of FDG-PET in predicting the viability of residual lesions were 66% and 91%, respectively. A lesion of rhabdomyosarcoma which obtained negative SUV in FDG-PET histological showed viable cells. A lesion of another rhabdomyosarcoma which showed positive SUV was evaluated as inflammatory lesion. Conclusions: Although FDG-PET showed excellent sensitivity and fair specificity in predicting the viability of residual lesions in patients with pediatric solid tumors, possibility of false-negativity should give us a caution not to rely on FDG-PET to judge the termination of therapy. No significant financial relationships to disclose.
Identification and Comparative Analysis of Thymidine Phosphorylase in the Plasma of Healthy Subjects and Cancer Patients: Brief Communication 2
Authors: John L. Pauly, Mark G. Schuller, Alan A. Zelcer, Tiina A. Kirss, Stacey S. Gore, Margit J. Germain
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Identification and Comparative Analysis of Thymidine Phosphorylase in the Plasma of Healthy Subjects and Cancer Patients: Brief Communication Get access John L. Pauly, John L. Pauly Search for other works by this author on: Oxford Academic PubMed Google Scholar Mark G. Schuller, Mark G. Schuller Search for other works by this author on: Oxford Academic PubMed Google Scholar Alan A. Zelcer, Alan A. Zelcer Search for other works by this author on: Oxford Academic PubMed Google Scholar Tiina A. Kirss, Tiina A. Kirss Search for other works by this author on: Oxford Academic PubMed Google Scholar Stacey S. Gore, Stacey S. Gore Search for other works by this author on: Oxford Academic PubMed Google Scholar Margit J. Germain Margit J. Germain Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 6, June 1977, Pages 1587–1590, https://doi.org/10.1093/jnci/58.6.1587 Published: 01 June 1977 Article history Received: 18 October 1976 Accepted: 19 January 1977 Published: 01 June 1977
Abstract 17814: Nadph Oxidase 4 Induces Cardiac Arrhythmia in Zebrafish
Authors: Yixuan Zhang, Hirohito Shimizu, Kin Lung Siu, Jau-Nian Chen, Hua Cai
Journal: Circulation (2012)

Accumulating evidence has indicated cardiac arrhythmias, particularly the most common form atrial fibrillation (AF), are associated with increased oxidative stress and structural remolding of the heart. We recently found that AF patients have elevated hydrogen peroxide production that is more than 3-fold of non-AF transplant patients, and this is correlated with an upregulation of cardiac NADPH oxidase 4 (NOX4) expression (Frontiers in Oxidant Physiology 2012 in press). The present study investigated whether overexpression of NOX4 in a zebrafish model induces cardiac arrhythmia. Full-length human NOX4 RNA (300 pg) was injected to one-cell stage embryos of cardiac specific GFP transgenic zebrafish. Interestingly, 52% of the NOX4 embryos developed arrhythmia at 24-30 hours postfertilization (hpf), while most of the control embryos had normal heart beats at the same stage (10% incidence). Quantification of the heart rates was carried out by video typing and software analysis. We discovered that the standard ...
Physical examination of the female cancer patient with sexual concerns: What oncologists and patients should expect from consultation with a specialist
Authors: Stacy Tessler Lindau, Emily M. Abramsohn, Shirley R. Baron, Judith Florendo, Hope K. Haefner, Anuja Jhingran, Vanessa Kennedy, Mukta K. Krane, David M. Kushner, Jennifer McComb, Diane F. Merritt, Julie E. Park, Amy Siston, Margaret Straub, Lauren Streicher
Journal: CA A Cancer Journal for Clinicians (2016)

Answer questions and earn CME/CNE Sexual concerns are prevalent in women with cancer or cancer history and are a factor in patient decision making about cancer treatment and risk‐reduction options. Physical examination of the female cancer patient with sexual concerns, regardless of the type or site of her cancer, is an essential and early component of a comprehensive evaluation and effective treatment plan. Specialized practices are emerging that focus specifically on evaluation and treatment of women with cancer and sexual function problems. As part of a specialized evaluation, oncologists and their patients should expect a thorough physical examination to identify or rule out physical causes of sexual problems or dysfunction. This review provides oncology professionals with a description of the physical examination of the female cancer patient with sexual function concerns. This description aims to inform anticipatory guidance for the patient and to assist in interpreting specialists' findings and recommendations. In centers or regions where specialized care is not yet available, this review can also be used by oncology practices to educate and support health care providers interested in expanding their practices to treat women with cancer and sexual function concerns. CA Cancer J Clin 2016;66:241‐263. © 2016 American Cancer Society .
To assess the response and toxicity of imatinib mesylate and low-dose cytarabine in imatinib non-responder chronic myeloid leukemia, chronic phase (CML-CP) patients: A pilot study
Authors: N. Singh, L. Kumar, V. Kochupillae, V. Raina, A. Sharma, T. Velpandian
Journal: Journal of Clinical Oncology (2007)

17507 Background: To overcome primary imatinib mesylate (Gleevec ) resistance, we used a combination of imatinib mesylate and low dose cytarabine to treat patients of CML-CP. Methods: Between January 2005 and July 2006, 30 patients (median age 34 years, range 20 to 57 years, M:F ratio 5:1) were enrolled. 2/30 patients had primary hematological and 28/30 had primary cytogenetic resistance. 7 patients had been pretreated with interferon alpha. Treatment consisted of imatinib 400mg daily and cytarabine 10mg subcutaneous daily for 10 days every month. Median of 5 cycles (range 3–6) was administered. Patients were monitored on outpatient basis with weekly blood counts. Bone marrow cytogenetics was done 3 monthly to assess cytogenetic response (CGR). Toxicity was recorded as per NCI CTC (version 2). Primary end points were response and toxicity at the end of 6 cycles. We measured plasma imatinib levels by HPLC in 20 of these patients (J Chromatography B 2004;84:431–34) and compared the levels with 20 patients who were imatinib responders. Results: 11/30 (37%) patients obtained major CGR including complete CGR in 6/30 (20%). None of the patients with primary hematological resistance responded. Grade 3/4 hematological and non hematological toxicities were seen in 3.33% (n=1) and6.66% (n=2) patients respectively. 8/30 (27%) patients discontinued treatment due to reversible cardiac arrest (n=1), hepatitis (n=1), progression to BC/AP (n=2), grade 4 thrombocytopenia (n=1), loss of CHR (n=2), and consent withdrawl (n=1). The mean plasma imatinib levels in non responders were significantly lower, compared to imatinib responders (0.70 micro moles vs 2.34 micro moles, p=0.002). Conclusions: Present study confirms the activity of low dose cytarabine and imatinib in patients having primary cytogenetic resistance. The reasons for low plasma imatinib levels among non responders and methods to circumvent so as to achieve higher plasma levels of imatinib needs further study. No significant financial relationships to disclose.
Validity of an automated telephonic system to assess exacerbation rates in prospective clinical COPD studies
Authors: Erik Bischoff, Lonneke Boer, Johan Molema, Reinier Akkermans, Chris van Weel, Jan Vercoulen, Tjard Schermer
Journal: European Respiratory Journal (2011)

Background:  Current methods for measuring COPD exacerbation rates in prospective studies are limited and often lack validity testing. We assessed the validity of an automated telephonic exacerbation assessment system (TEXAS) as a novel tool to measure COPD exacerbation rates.   Methods:  In a 1-yr prospective cohort study COPD patients were called bi-weekly by TEXAS to record respiratory symptom changes, unscheduled healthcare utilization, and use of respiratory medication. Home visit observations within 3 days after a call were used to verify the responses of the patients to TEXAS. Diagnostic test characteristics were assessed using 4 common definitions of exacerbation. Detection rates, compliance, and patient preference were compared with the results of conventional methods, i.e. paper diary cards and medical record review.   Results:  During follow-up 1,824 successful TEXAS calls were recorded in 86 COPD patients (22.1% female, mean age 66.5 years, mean post bronchodilator FEV1 53.4% predicted). 292 home visits were performed (median: 4 per patient, interquartile range: 3 to 5). Overall, validity of TEXAS was high with sensitivities and specificities between 66% and 98%, but differed between the four exacerbation definitions. Detection rates were higher with TEXAS than with the conventional methods. Compliance was higher with TEXAS than with diary cards, but patient preferences did not differ.   Conclusions:  TEXAS appears to be a valid tool to measure COPD exacerbation rates and it may be used with various exacerbation definitions. In the interpretation of studies on exacerbation outcomes it should be realized that the exacerbation rate much depend on the detection method used.
Pure autologous tumor cells (TC) and dendritic cells (DC) with GM-CSF: Patient-specific vaccine for metastatic melanoma
Authors: R. O. Dillman, S. R. Selvan, P. M. Schiltz, K. Allen, C. Depriest, E. F. McClay, N. M. Barth, P. F. Sheehy, C. De Leon, C. Peterson
Journal: Journal of Clinical Oncology (2004)

7547 Background: DC loaded with TC is a promising approach for vaccine therapy. The novel aspect of the product used in this trial is the use of irradiated melanoma TC from autologous cell lines incubated with interferon-gamma (IFN) to enhance expression of HLA and tumor associated antigens. Methods: Pure cultures of melanoma TC are expanded to 108 cells, incubated with 103 U/ml IFN for 72 hrs, irradiated, then cryopreserved. DC are generated from peripheral blood by incubating mononuclear cells in AIM V medium with 1000 U/ml GM-CSF and 1000 U/ml IL-4 for one week. DC and TC are co-incubated overnight, then cryopreserved in aliquots of about 107 cells. For treatment, vial contents are suspended in 500 mg GM-CSF for each s.c. injection. After a baseline delayed-type hypersensitivity (DTH) test to an i.d. injection of 106 irradiated TC at week-0, patients receive s.c. vaccinations weekly × 3, then monthly × 5. The DTH test to autologous TC is repeated at week-4. Results: Cell lines have been established for 75% of patients and vaccines prepared from 60% of the lines. As of 12/01/03, 21 patients had been entered. 16 had received prior i.v. IL-2 and/or chemotherapy; 7 had measurable disease at entry. 138 vaccine injections have been administered; 16 patients have completed the entire series. At the median follow-up of 8 mos, progression-free survival is 51%. All 21 patients were still alive with the longest followed more than 2.5 years since starting the vaccine. The only common adverse event is mild erythema at the injection site. One patient had an anaphylactoid reaction following her 8th and final injection. No patients were anergic at baseline, but all were DTH-. 8/21 (38%) subsequently exhibited an immune response to autologous tumor; 5 became DTH+ at 4 weeks and 3 more at 6 mos. Conclusions: This patient-specific DC/autologous TC vaccine is feasible and well tolerated. The DTH conversion rate is encouraging, as are the progression-free and overall survival rates. No significant financial relationships to disclose.
Therapeutic hypothermia does not improve outcomes in traumatic brain injury, study finds
Authors: Susan Mayor
Journal: BMJ (2015)

Therapeutic hypothermia does not improve recovery or disability in people with traumatic brain injury when compared with standard care, a large European study published in the New England Journal of Medicine has shown.1

Hypothermia improves outcomes after cardiac arrest, and guidelines recommend its use. It has also been shown to reduce intracranial hypertension in people with traumatic brain injury, but its effect on reducing disability has previously been unclear.

To investigate this, researchers randomised adults …